BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
340.61
-0.03 (-0.01%)
At close: Nov 28, 2025, 1:00 PM EST
337.96
-2.65 (-0.78%)
After-hours: Nov 28, 2025, 4:59 PM EST
BeOne Medicines AG Stock Forecast
Stock Price Forecast
The 12 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $369.5, which forecasts a 8.48% increase in the stock price over the next year. The lowest target is $312 and the highest is $408.
Price Target: $369.5 (+8.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 4 |
| Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $400 | Strong Buy | Initiates | $400 | +17.44% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $395 → $408 | Buy | Maintains | $395 → $408 | +19.79% | Nov 18, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $399 → $405 | Strong Buy | Maintains | $399 → $405 | +18.90% | Nov 10, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $374 → $395 | Buy | Maintains | $374 → $395 | +15.97% | Nov 7, 2025 |
| Citizens | Citizens | Buy Maintains $348 → $396 | Buy | Maintains | $348 → $396 | +16.26% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
37.64B
from 27.81B
Increased by 35.34%
Revenue Next Year
46.09B
from 37.64B
Increased by 22.45%
EPS This Year
1.04
from -44.70
EPS Next Year
3.13
from 1.04
Increased by 200.88%
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.9B | 49.9B | |||
| Avg | 37.6B | 46.1B | |||
| Low | 36.0B | 43.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.4% | 32.5% | |||
| Avg | 35.3% | 22.5% | |||
| Low | 29.4% | 15.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.56 | 3.68 | |||
| Avg | 1.04 | 3.13 | |||
| Low | 0.49 | 2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 253.3% | |||
| Avg | - | 200.9% | |||
| Low | - | 121.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.